China-based vaccines developer Jiangsu Recbio Technology has raised HK$765 million ($97.7 million) in an initial public offering (IPO) in Hong Kong on Thursday. The funds will go towards challenging the dominant foreign player Merck & Co in China’s highly-concentrated HPV (Human papillomavirus) vaccine market.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in